KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancerJianming Xu, Qian Wang, Yanqiao Zhang et al.|European Journal of Cancer|2022Cited by 54
A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).Jianming Xu, Qian Wang, Rongrui Liu et al.|Journal of Clinical Oncology|2022Cited by 6
Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.Jifang Gong, Lin Shen, Lei Chen et al.|Journal of Clinical Oncology|2023Cited by 6